S&P 500

5.277,51

0,80%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (SAGE) Notícias

SAGE

Sage Therapeutics (SAGE)

Sage Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:SAGE

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
07/05/2024	07:30	Business Wire	Sage Therapeutics to Participate in Upcoming May Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
25/04/2024	07:30	Business Wire	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
17/04/2024	07:30	Business Wire	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	NASDAQ:SAGE	Sage Therapeutics Inc
11/04/2024	07:30	Business Wire	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
28/02/2024	08:30	Business Wire	Sage Therapeutics to Present at Upcoming March Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
21/02/2024	18:35	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:SAGE	Sage Therapeutics Inc
15/02/2024	19:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
14/02/2024	09:49	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SAGE	Sage Therapeutics Inc
14/02/2024	09:20	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:SAGE	Sage Therapeutics Inc
14/02/2024	08:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
14/02/2024	08:30	Business Wire	Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
31/01/2024	08:30	Business Wire	Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
23/01/2024	10:13	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:SAGE	Sage Therapeutics Inc
08/01/2024	08:32	Business Wire	Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:SAGE	Sage Therapeutics Inc
08/01/2024	08:30	Business Wire	Sage Therapeutics Announces Changes to Board of Directors	NASDAQ:SAGE	Sage Therapeutics Inc
02/01/2024	08:30	Business Wire	Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
19/12/2023	10:32	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:SAGE	Sage Therapeutics Inc
19/12/2023	10:30	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SAGE	Sage Therapeutics Inc
14/12/2023	08:30	GlobeNewswire Inc.	ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.	NASDAQ:SAGE	Sage Therapeutics Inc
08/12/2023	11:00	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NASDAQ:SAGE	Sage Therapeutics Inc
08/12/2023	10:30	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SAGE	Sage Therapeutics Inc
08/11/2023	08:30	Business Wire	Sage Therapeutics to Present at Upcoming November Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
07/11/2023	09:29	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SAGE	Sage Therapeutics Inc
07/11/2023	09:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SAGE	Sage Therapeutics Inc
07/11/2023	08:30	Business Wire	Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
24/10/2023	07:30	Business Wire	Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023	NASDAQ:SAGE	Sage Therapeutics Inc
18/10/2023	08:10	Dow Jones News	Sage Therapeutics Gets FDA Orphan Designation for SAGE-718 in Huntington's	NASDAQ:SAGE	Sage Therapeutics Inc
18/10/2023	07:30	Business Wire	Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease	NASDAQ:SAGE	Sage Therapeutics Inc
06/09/2023	07:30	Business Wire	Sage Therapeutics to Present at Upcoming September Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
31/08/2023	07:30	Business Wire	Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement	NASDAQ:SAGE	Sage Therapeutics Inc